

# Reviews of Outsourcing Facilities During COVID-19

Edisa L. Gozun, Pharm.D. Acting Division Director



### **Pre-Operational Reviews**

- Requests from outsourcing facilities and compounders considering registering as outsourcing facilities
  - Compliance with conditions of section 503B
  - Compliance with CGMP requirements
  - Expansion plans/proposed facility design



### **Pre-Operational On-Site Evaluations**

- Prior to outsourcing facilities initiating drug production for distribution
- FDA will be on-site to assess
  - Facility design
  - Standard operating procedures
  - Other conditions that are critical to producing sterile drug products
- However, due to the pandemic, pre-operational on-site evaluations are currently on hold





- Submit request to <u>Compounding@fda.hhs.gov</u>
- Additional information
  - Statement of purpose and objective for the meeting
  - List of individuals who will be attending the meeting
  - Proposed meeting duration and suggested dates/time
  - Proposed format of the meeting
  - Proposed agenda
  - List of specific questions



# **Remote Regulatory Assessments**

- To work with outsourcing facilities to achieve control and compliance with applicable sections of FDCA during the COVID-19 pandemic
- Provide FDA with an understanding of firm's operational state

www.fda.gov 5



### **Remote Regulatory Assessments**

- Outsourcing facilities requesting preoperational site evaluations
- Newly registered outsourcing facilities
- Currently registered outsourcing facilities

www.fda.gov



# Remote Regulatory Assessments

- Type of information for FDA review could include:
  - Facility design diagrams
  - Adverse event reports
  - Organizational chart
  - Product labels
  - Investigation reports



# **Questions?**

